HK-listed WuXi XDC hits 10-month peak on solid first-half results
BUZZ-HK-listed WuXi XDC hits 10-month peak on solid first-half results ** Shares of Chinese drugmaker WuXi XDC 2268.HK jump 12% to HK$78.2, their highest point since October 9, 2025
** Stock posts its biggest intraday pct rise since March 2025
** Stock is top pct gainer in Hang Seng Biotech Index .HSBIO, which climbs 1.4%
** The WuXi Biologics-backed 2269.HK company says its first-half revenue up 37% y/y at 3.7 billion yuan ($550.19 million) with adjusted net profit attributable up 37.4% y/y at 1.03 billion yuan and gross profit margin up 0.9 percentage points to 37%
** Shares of WuXi Biologics climb 4.9% to HK$51, their biggest intraday pct gain since August 18
** YTD, WuXi XDC stock up 26.7%, WuXi Biologics up 59.2%, Hang Seng Biotech Index .HSBIO up 11.3%
($1 = 6.7249 Chinese yuan)
(Reporting by Donny Kwok)
Recent news on WuXi XDC Cayman
See all newsBrief: Wuxi Apptec Announces Disposal Of 53.5 Mln Shares In Wuxi XDC Via Block Trade
HK-listed WuXi XDC hits 10-month peak on solid first-half results
Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisition
Brief: WuXi XDC Cayman Posts H1 Revenue Of RMB3,701.4 Million
WuXi XDC climbs on share purchases under company scheme